| Stage | CON | % of rev | HLIO | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $606M | 100.00% | $232M | 100.00% | CON ×2.61 |
| Gross profit | $192M | 31.70% | $80M | 34.58% | HLIO +2.9pp |
| Operating income | $115M | 18.99% | $33M | 14.01% | CON +5.0pp |
| Pre-tax income | $89M | 14.74% | $28M | 12.12% | CON +2.6pp |
| Net income | $67M | 11.10% | $22M | 9.44% | CON +1.7pp |
| Stage | CON | HLIO | Gap · A − B |
|---|---|---|---|
| Revenue | $606M100.00% | $232M100.00% | CON ×2.61 |
| Gross profit | 31.70%$192M | 34.58%$80M | HLIO +2.9pp |
| Operating income | 18.99%$115M | 14.01%$33M | CON +5.0pp |
| Pre-tax income | 14.74%$89M | 12.12%$28M | CON +2.6pp |
| Net income |
| 11.10%$67M |
| 9.44%$22M |
| CON +1.7pp |
No disclosed counterparties: HLIO.
None